Skip to main content

Table 1 Current non-pharmaceutical disease-modifying ongoing clinical trials

From: Novel targeted therapies for Parkinson’s disease

Mechanism Intervention ClinTrial Indentifier Phase Τarget population Primary outcome Other secondary outcomes of interest Sponsor
Gene therapies Vector genome: VY-AADC02 NCT03562494 II Moderate to Advanced PD with motor Fluctuations Changes in ON time without troublesome dyskinesia . Neurocrine Biosciences
  Lentiviral vector:
NCT03720418 I/II Bilateral PD AE, SAE, Changes in MRI . Sio Gene Therapies
Neuromodulation MRgFUS NCT04002596
NA Advanced PD AE,
Changes in CRST,
Changes in MDS-UPDRS
. InSightec
Neuromodulation rTMS NCT04238000 NA PD Motor Outcomes . Fondazione Europea di Ricerca Biomedica Ferb Onlus
   NCT04431570 NA PD, freezing of gait Changes in FOGT fMRI Peking Union Medical College Hospital
   NCT04116216 II PD Changes in MDS-UPDRS part III . Universidade Federal de Pernambuco
   NCT03836950 I/II PD Changes in Cognitive Outcomes . VA Office of Research and Development
   NCT02346708 NA PD with MCI Changes in magnetoencephalography connectivity measures . University of Colorado, Denver
   NCT03552861 NA PD with Depression or Cognitive Impairment Changes in HAMD and BDI . Guangdong Provincial People’s Hospital
  1. AE Adverse Events, BDI Beck Depression Inventory, CRST Clinical Rating Scale for Tremor, fMRI functional Magnetic Resonance Imaging, FOGT Freezing Of Gait Questionnaire, HAMD Hamilton Depression Scale, MCI Mild Cognitive Impairment, MDS-UPDRS MDS-Unified Parkinson’s Disease Rating Scale, MRgFUS Magnetic Resonance Guided Focused Ultrasound, MRI Magnetic Resonance Imaging, NA Not Applicable; rTMS Repetitive Transcranial Magnetic Stimulation, PD Parkinson’s Disease